Expo Technologies expands operations in Europe

St. Louis, MO - 18 MAY 2009 - Expo Technologies announces the addition of Colin Dye to the Expo Technologies PAT group. Colin joins Expo as their European Business Development Director and will be responsible for the effective communication with and support of the PAT division’s existing and new customer base.
"This is consistent with our strategy to become the PAT implementation partner of choice for the pharmaceutical community", Paul Davies, President and General Manager, explained, "Following the acquisition of leading PAT software company, SpectrAlliance, in 2007, we have seen a significant increase in business activity in the US and Europe. We needed someone with the right experience to lead the support of that growth in Europe." continued Davies.

Colin joins Expo Technologies with more than a dozen years of PAT experience and significantly more than that in spectroscopy. "I am delighted to be involved in such an exciting project, here at Expo." explained Dye. "I have been involved in PAT for many years, before the phrase "PAT" was even coined and have come to appreciate that it is just as much about practicality of implementation as about the analytical measurement. Expo’s unique mix of spectroscopy, engineering expertise, PAT focused software and robust product life cycle management has made them one of the leaders in PAT implementation and I wanted to be a part of that."

Expo Technologies’ mission is to become the PAT implementation partner of choice for the pharmaceutical industry through meticulously documented and controlled specifications, extensive testing based upon formal risk assessment methodologies, and the design and development of robust systems based upon specific application solutions.

Find out why leading pharmaceutical companies have partnered with Expo Technologies for their PAT deployment strategies - visit us on the web at:www.expoforpat.com

For more information on Expo Technologies: www.expoforpat.com, e-mail pharma@expoforpat.com

<< Back to News & Press main page.